Zelira Therapeutics' Quarterly Cash Flow Report for Quarter Ended 30 June 2024

Zelira Therapeutics Limited (ASX: $ZLD) has released its Quarterly Cash Flow Report for the quarter ended 30 June 2024. The report highlights the company's financial activities, including the securing of a US$1.4 million working capital loan note with Osagie Imasogie, which is set to become a convertible loan note with a conversion price of US$0.40, subject to shareholder approval and the upcoming 2024 Annual General Meeting.

Executive Commentary on Financial Activities

The company has successfully secured a significant working capital loan note, which will provide the necessary financial support for our operations. This funding will enable us to pursue our strategic objectives and continue the development of our innovative therapeutics. We are confident that this financial arrangement will contribute to the long-term success of Zelira Therapeutics.

Summary of Quarterly Cash Flow Report and Outlook

Zelira Therapeutics' Quarterly Cash Flow Report for the quarter ended 30 June 2024 demonstrates the company's proactive approach to securing financial support for its operations. The announcement of the US$1.4 million working capital loan note with a potential conversion to a convertible loan note reflects the company's commitment to ensuring adequate funding for its strategic initiatives. Looking ahead, the company aims to leverage this financial support to advance its business objectives and drive growth in the therapeutic industry.